Development and Validation of a Thoracic Aortic Calcification-Based Nomogram for Early Myocardial Injury in Breast Cancer Patients
Lingqu Zhou, Liangjiao Wang, Junjie Wang, Zirui Zhou, Xiuquan Zhang, Ziyue Zhong, Qi Guo, Yinyin Zhang · 2026
Read Development and Validation of a Thoracic Aortic Calcification-Based Nomogram for Early Myocardial Injury in Breast Cancer Patients by Lingqu Zhou, Liangjiao Wang, Junjie Wang, Zirui Zhou, Xiuquan Zhang, Ziyue Zhong, Qi Guo, Yinyin Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607559.txt.
Introduction
Lingqu Zhou and co-authors built a tool to flag breast cancer patients at risk of heart harm. Some cancer drugs injure the heart muscle early in treatment. The team looked back at over five hundred patients treated at one hospital. All had chest scans and repeat blood tests for a heart strain marker.
They tested many traits to find which ones warned of early injury. Four stood out: the strain marker at baseline, a blood fat measure, calcium build up in the chest aorta, and one class of targeted drug. Joined in a chart called a nomogram, the four sorted patients into clear risk groups. The chart held up well on a fresh set of patients the builders had set aside.
Catalog record
| CREATOR | Lingqu Zhou, Liangjiao Wang, Junjie Wang, Zirui Zhou, Xiuquan Zhang, Ziyue Zhong, Qi Guo, Yinyin Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Development and Validation of a Thoracic Aortic Calcification-Based Nomogram for Early Myocardial Injury in Breast Cancer Patients Authors: Lingqu Zhou, Liangjiao Wang, Junjie Wang, Zirui Zhou, Xiuquan Zhang, Ziyue Zhong, Qi Guo, Yinyin Zhang Published: 2026 ABSTRACT Early identification of patients with breast cancer who are at increased risk of treatment-related myocardial injury may support individualized cardiovascular surveillance. This retrospective study included 551 patients treated at Sun Yat-sen Memorial Hospital between January 2014 and December 2021. All patients had chest computed tomography data and at least three high-sensitivity cardiac troponin T (hs-cTnT) measurements. Early myocardial injury was defined as hs-cTnT > 14 ng/L within 6 months after treatment. Patients were randomly divided into training (n = 366) and validation (n = 185) cohorts. Candidate predictors were identified using univariable Cox regression and least absolute shrinkage and selection operator regression. A multivariable Cox model was then used to construct the nomogram. Baseline hs-cTnT, high-density lipoprotein cholesterol, thoracic aortic calcification score, and anti-human epidermal growth factor receptor 2 therapy were retained as independent predictors. In the validation cohort, the nomogram showed good discrimination, with an area under the receiver operating characteristic curve of 0.901 and a concordance index of 0.882. Calibration curves indicated agreement between predicted and observed risks. Decision curve analysis suggested clinical utility, while risk stratification identified distinct groups in both cohorts (p < 0.001). This thoracic aortic calcification-based nomogram may support the identification of patients at high risk of early myocardial injury after anticancer therapy. 1. Introduction Cardio-oncology focuses on the prevention, detection, and management of cardiovascular complications in patients with cancer [1,2]. Breast cancer is the most common malignancy among women worldwide, and advances in screening and anticancer therapy have substantially improved survival [3,4]. Despite these advances, cardiovascular toxicity remains a major challenge in breast cancer care [5]. Myocardial injury, reflected by elevated cardiac troponin levels during or after treatment, is an early manifestation of cancer therapy-related cardiovascular toxicity (CTR-CVT) [1,6]. High-sensitivity cardiac troponin T (hs-cTnT) is widely available and can detect subclinical myocardial injury before overt cardiac dysfunction. This biomarker may therefore support early risk stratification and individualized surveillance [7,8,9]. Imaging markers of subclinical vascular damage may complement conventional risk factors in individualized cardiovascular risk assessment [10]. Vascular calcification is an imaging marker of subclinical atherosclerosis and cardiovascular vulnerability and has been associated with future cardiovascular events and mortality [11]. In patients with breast cancer, coronary artery calcification (CAC) and thoracic aortic calcification (TAC) can often be assessed on chest computed tomography (CT) performed for pretreatment staging, radiotherapy planning, or other clinical indications [12,13]. These imaging findings may provide additional information on baseline cardiovascular risk before anticancer treatment. However, evidence remains limited regarding the association between baseline vascular calcification and subsequent myocardial injury after breast cancer treatment. Few prediction models have incorporated vascular calcification when assessing myocardial injury risk in this population. Nomograms are practical prediction tools that integrate multiple clinical variables to estimate individualized risk [14]. They have been widely used in oncology and cardiovascular research to support risk assessment and clinical decision-making [15,16]. Therefore, a nomogram incorporating clinically available variables may help predict the risk of myocardial injury after breast cancer treatment. We aimed to identify predictors of myocardial injury within 6 months after breast cancer treatment and to develop and validate a multivariable Cox regression-based prognostic nomogram. The model was developed in a training cohort and evaluated in a validation cohort for discrimination, calibration, and clinical utility. 2. Methods 2.1. Data Source and Study Population We retrospectively screened patients with breast cancer admitted to Sun Yat-sen Memorial Hospital between January 2014 and December 2021. Patients were eligible if they had at least three hs-cTnT measurements and at least 6 months of follow-up. Eligible patients were randomly divided into training and internal validation cohorts at a ratio of 2:1. Patients were further classified according to whether myocardial injury occurred within 6 months after breast cancer treatment. The nomogram was developed using the training cohort and internally validated in the validation cohort. The exclusion criteria were as follows: (1) unavailable hs-cTnT data at baseline or during follow-up, or baseline hs-cTnT > 14 ng/L; (2) absence of chest CT data; (3) coexisting malignancies or autoimmune diseases requiring immunosuppressive or antitumor-related treatment; (4) pregnancy or lactation; (5) history of myocardial infarction or severe heart failure, or current acute myocardial infarction, myocarditis, severe arrhythmia, severe infection, or renal dysfunction; and (6) age < 18 years or substantial missing data on key clinical variables (Supplementary Figure S1). 2.2. Clinical Data Collection Baseline clinical data were extracted from electronic medical records at initial admission. The collected variables included age, sex, body mass index (BMI), vital signs, admission status, medical history, cancer-related diagnosis, laboratory test results, echocardiographic findings, chest CT findings, and treatment-related information. The primary endpoint was myocardial injury within 6 months after breast cancer treatment. Myocardial injury was defined as an hs-cTnT level > 14 ng/L at any time during follow-up [8,17]. Hs-cTnT was measured using the Elecsys Troponin T hs assay on a cobas e601 analyzer (Roche Diagnostics, Mannheim, Germany). The analytical measurement range was 3–10,000 ng/L, and the 99th-percentile upper reference limit was 14 ng/L. For patients with elevated hs-cTnT during follow-up, medical records around the time of measurement were reviewed, and elevations attributable to acute myocardial infarction, myocarditis, pulmonary embolism, severe infection, acute renal dysfunction, atrial fibrillation, or other clinically significant arrhythmias were not classified as endpoint events. 2.3. Calculation of Vascular Calcification Scores Vascular calcification was assessed using a previously reported noninvasive visual scoring method [18,19,20]. Axial CT images were reviewed, and calcification severity was graded according to the definitions provided in Supplementary Table S1. CAC was assessed separately in the four major coronary artery branches, with each branch assigned a score from 0 to 3. The branch scores were summed to obtain a total CAC score ranging from 0 to 12. TAC was assessed in the ascending aorta, descending aorta, and branches of the aortic arch. The ascending and descending aorta were each scored from 0 to 3, and the aortic arch branches were scored from 0 to 2, yielding a total TAC score ranging from 0 to 8. CAC was categorized as absent, mild, moderate, or severe according to scores of 0, 1–2, 3–5, and ≥6, respectively. TAC was categorized as absent, mild, moderate, or severe according to scores of 0, 1–2, 3–4, and ≥5, respectively. All CT images were evaluated for CAC and TAC by three assessors, including one board-certified radiologist with 10 years of experience and two research physicians with 2 and 3 years of experience in chest CT interpretation. Interobserver agreement for the TAC score was assessed using a two-way random-effects intraclass correlation coefficient (ICC) with absolute agreement, based on the independent scores assigned by the three assessors before consensus resolution. The interobserver agreement for TAC scoring was good, with an ICC of 0.89 (95% CI, 0.87–0.91). 2.4. Statistical Analysis The normality of continuous variables was assessed using the Kolmogorov–Smirnov test. Normally distributed continuous variables were presented as mean ± standard deviation (SD) and compared using Student’s t test. Non-normally distributed continuous variables were presented as median (interquartile range) and compared using the Mann–Whitney U test. Categorical variables were presented as